Insider Selling: Progyny (NASDAQ:PGNY) CFO Sells 21,303 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 21,303 shares of Progyny stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $25.50, for a total transaction of $543,226.50. Following the completion of the transaction, the chief financial officer directly owned 48,358 shares in the company, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded down $0.45 during mid-day trading on Wednesday, hitting $25.40. The stock had a trading volume of 1,526,154 shares, compared to its average volume of 1,440,221. Progyny, Inc. has a 12-month low of $13.50 and a 12-month high of $27.25. The company has a market cap of $2.19 billion, a PE ratio of 40.32, a P/E/G ratio of 2.11 and a beta of 1.29. The company’s 50 day moving average is $21.13 and its 200-day moving average is $21.94.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.06. The company had revenue of $313.35 million for the quarter, compared to the consensus estimate of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The company’s revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. On average, equities research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PGNY. Vanguard Group Inc. lifted its stake in shares of Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after purchasing an additional 235,513 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its position in shares of Progyny by 2.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,931,249 shares of the company’s stock worth $41,560,000 after buying an additional 39,666 shares during the last quarter. Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Progyny by 33.1% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock valued at $35,649,000 after acquiring an additional 412,395 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Progyny by 79.2% in the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after acquiring an additional 696,447 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on PGNY. Raymond James Financial set a $28.00 target price on Progyny in a research note on Friday, August 8th. JPMorgan Chase & Co. upped their price objective on shares of Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. KeyCorp upgraded shares of Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price target on the stock in a report on Tuesday, November 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price target (up from $26.00) on shares of Progyny in a research note on Friday, August 8th. Finally, Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Progyny has an average rating of “Moderate Buy” and a consensus target price of $27.33.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.